|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
KR101163424B1
(ko)
|
2003-12-30 |
2012-07-13 |
메르크 파텐트 게엠베하 |
Ｉｌ－７ 융합 단백질
|
|
EP1699821B1
(en)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
RU2450830C2
(ru)
|
2005-10-21 |
2012-05-20 |
Чугаи Сейяку Кабусики Кайся |
Средства для лечения кардиопатии
|
|
CN101346395A
(zh)
|
2005-12-30 |
2009-01-14 |
默克专利有限公司 |
阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
|
|
JP5754875B2
(ja)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
筋再生促進剤
|
|
ES2433380T3
(es)
*
|
2006-11-30 |
2013-12-10 |
Medimmune Limited |
Anticuerpos específicos para el complejo de interleucina 6 y el receptor de interleucina 6
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
MX2009007830A
(es)
|
2007-01-23 |
2009-10-07 |
Univ Shinshu |
Inhibidor de rechazo cronico.
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
DK2164514T3
(en)
|
2007-05-21 |
2017-02-27 |
Alderbio Holdings Llc |
Antibodies to IL-6 and its use
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
WO2009109584A1
(en)
*
|
2008-03-07 |
2009-09-11 |
Ferring International Center S. A. |
ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
|
|
JP2011520898A
(ja)
*
|
2008-05-13 |
2011-07-21 |
ノビミューン エスアー |
抗ｉｌ−６／ｉｌ−６ｒ抗体およびそれらの使用方法
|
|
TW201503898A
(zh)
|
2008-06-05 |
2015-02-01 |
Chugai Pharmaceutical Co Ltd |
神經浸潤抑制劑
|
|
US8188235B2
(en)
*
|
2008-06-18 |
2012-05-29 |
Pfizer Inc. |
Antibodies to IL-6 and their uses
|
|
MX2011000071A
(es)
*
|
2008-07-02 |
2011-05-03 |
Emergent Product Dev Seattle |
Inmunoterapeuticos de interleucina-6 (il6).
|
|
WO2010036460A2
(en)
*
|
2008-09-29 |
2010-04-01 |
Centocor Ortho Biotech Inc. |
Anti-cd147 antibodies, methods, and uses
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
KR20110091780A
(ko)
|
2008-11-25 |
2011-08-12 |
앨더 바이오파마슈티컬즈, 인코포레이티드 |
악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ６의 길항제
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
AU2010238858A1
(en)
|
2009-04-22 |
2011-12-08 |
Merck Patent Gmbh |
Antibody fusion proteins with modified FcRn binding sites
|
|
MX2011012047A
(es)
|
2009-05-13 |
2011-12-14 |
Genzyme Corp |
Inmunoglobulinas humanas anti-cd52.
|
|
WO2011006273A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Eva Kovacs-Benke |
Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
|
|
SG178190A1
(en)
*
|
2009-07-31 |
2012-03-29 |
Shin Maeda |
Cancer metastasis inhibitor
|
|
BR112012003686B1
(pt)
*
|
2009-08-19 |
2021-09-21 |
Merck Patent Gmbh |
Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
EP2504032A4
(en)
|
2009-11-24 |
2013-06-19 |
Alderbio Holdings Llc |
IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
|
|
EP2516467A2
(en)
|
2009-12-23 |
2012-10-31 |
Emergent Product Development Seattle, LLC |
Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
|
|
RS63800B1
(sr)
|
2010-05-28 |
2022-12-30 |
Chugai Pharmaceutical Co Ltd |
Poboljšanje antitumorskog odgovora t ćelije
|
|
US8992908B2
(en)
|
2010-11-23 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of oral mucositis
|
|
US20140255405A1
(en)
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
|
US11492383B2
(en)
|
2011-06-24 |
2022-11-08 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US20140315956A1
(en)
*
|
2011-07-29 |
2014-10-23 |
Nationwide Children's Hospital |
Small molecule inhibitors of il-6 and uses thereof
|
|
WO2013059548A1
(en)
*
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
|
KR102149206B1
(ko)
*
|
2012-11-08 |
2020-08-31 |
세센 바이오, 아이엔씨. |
인터루킨-6의 길항제 및 이의 용도
|
|
EP2970496B1
(en)
|
2013-03-12 |
2018-07-18 |
Institute of Arthritis Research LLC |
Immunologically active polypeptide
|
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
|
PL3044323T3
(pl)
|
2013-09-13 |
2022-06-27 |
F.Hoffmann-La Roche Ag |
Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
|
|
SG11201601823TA
(en)
|
2013-09-13 |
2016-04-28 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
|
CN103897061B
(zh)
*
|
2014-03-25 |
2017-06-16 |
宝船生物医药科技(上海)有限公司 |
阻断西妥昔单抗和egfr结合的抗体、其试剂盒及杂交瘤细胞
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
SI3215530T1
(sl)
*
|
2014-11-07 |
2020-02-28 |
Sesen Bio, Inc. |
Izboljšana protitelesa IL-6
|
|
EP3226888B1
(en)
*
|
2014-12-01 |
2021-04-21 |
Ferring B.V. |
Administration of a selective il-6-trans-signalling inhibitor
|
|
KR20240131465A
(ko)
*
|
2014-12-01 |
2024-08-30 |
훼링 비.브이. |
선택적 il-6-트랜스-신호전달 억제제 조성물
|
|
RU2716136C2
(ru)
|
2015-07-02 |
2020-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Бициклические лактамы и способы их применения
|
|
BR112018017031A2
(pt)
|
2016-02-23 |
2019-01-22 |
Sesen Bio Inc |
formulações de antagonista de il-6 e usos das mesmas
|
|
JP7349359B2
(ja)
|
2016-10-17 |
2023-09-22 |
エフ． ホフマン－ラ ロシュ アーゲー |
二環式ピリドンラクタム及びその使用方法。
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
JP7630906B2
(ja)
|
2017-02-01 |
2025-02-18 |
イェール・ユニヴァーシティー |
利尿薬耐性の治療
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
|
WO2019078344A1
(ja)
|
2017-10-20 |
2019-04-25 |
学校法人兵庫医科大学 |
抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
|
|
CN109867723B
(zh)
*
|
2017-12-05 |
2022-06-17 |
南京金斯瑞生物科技有限公司 |
抗人il6单克隆抗体及其制备方法和用途
|
|
SG11202006157VA
(en)
|
2018-01-05 |
2020-07-29 |
Corvidia Therapeutics Inc |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
|
EP3781571B1
(en)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
|
AU2020259884A1
(en)
|
2019-04-17 |
2021-10-07 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
|
CN114375205A
(zh)
|
2019-06-20 |
2022-04-19 |
武田药品工业株式会社 |
用基于病毒的基因疗法进行治疗的方法
|
|
CN111057152B
(zh)
*
|
2019-12-11 |
2022-03-11 |
中国人民解放军第四军医大学 |
一种抗人IL-6Ra单克隆抗体及其应用
|
|
JP2023042974A
(ja)
*
|
2021-09-15 |
2023-03-28 |
シスメックス株式会社 |
抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体
|
|
CN119080929B
(zh)
*
|
2023-06-05 |
2025-08-12 |
东莞市朋志生物科技有限公司 |
抗白介素6抗体、检测白介素6的试剂和试剂盒
|